What Are Puberty Blockers and How Do They Work?

Puberty blockers are medications that temporarily halt the hormonal cascade responsible for puberty. They work by overriding the brain’s signaling system so that the body stops producing the sex hormones (estrogen and testosterone) that drive physical changes like breast development, voice deepening, and growth spurts. The drugs have been used in pediatric medicine since the 1980s, initially to treat children who entered puberty abnormally early, and more recently as part of gender-affirming care for transgender adolescents. How they function is straightforward pharmacology, but what happens during and after treatment is the subject of active and sometimes contentious research.

How They Suppress Puberty

Puberty starts when a part of the brain called the hypothalamus begins releasing gonadotropin-releasing hormone (GnRH) in pulses. Those pulses tell the pituitary gland to secrete two other hormones, which in turn signal the ovaries or testes to produce estrogen or testosterone. Puberty blockers, more precisely called GnRH agonists, are synthetic versions of GnRH. They might sound like they should speed things up, but the opposite happens: by delivering a continuous, non-pulsatile flood of GnRH-like activity, they overwhelm the pituitary’s receptors. The receptors essentially shut down, a process called desensitization, and the downstream production of sex hormones drops to prepubertal levels.¹

A separate class of drugs, GnRH antagonists, blocks the receptor directly rather than wearing it out through overstimulation. Both classes achieve the same result: suppressing sex hormones. The agonists are far more commonly used in pediatric settings because they have a longer track record and come in convenient long-acting formulations. GnRH antagonists are used more often in adults for conditions like prostate cancer, endometriosis, and assisted reproduction.²

Where They Came From

The story traces back to 1971, when researcher Andrew Schally announced the chemical structure of natural GnRH at an Endocrine Society meeting. That discovery, which eventually earned Schally a Nobel Prize, opened the door to creating synthetic versions. Over the following decades, more than 2,000 GnRH analogs were synthesized, each tweaked to be more potent or longer-lasting than natural GnRH.³ By the mid-1980s, clinicians began using these drugs to treat children with central precocious puberty, and that remains the most common pediatric application today.

The Original Pediatric Use: Central Precocious Puberty

Central precocious puberty (CPP) is a condition where the brain’s puberty signals switch on too early, sometimes as young as age two or three. Left untreated, these children go through full puberty years ahead of their peers. Beyond the social and psychological difficulties, early puberty causes the growth plates in bones to fuse prematurely, which can leave a child significantly shorter as an adult than they would have been otherwise.

GnRH agonists became the standard treatment for CPP because they pause the process until a more typical age. In girls with progressive CPP who were treated with GnRH agonists, final adult height was significantly greater than the height predicted before treatment began, with treated girls reaching an average of about 159 cm compared to a predicted 153.5 cm without treatment.⁴ Growth rate and the pace of bone maturation both normalize on treatment, slowing down to match the child’s actual age.⁵ This is the use case with the longest track record, spanning roughly four decades, and it provides much of the safety data that informs other applications.

Puberty Blockers in Gender-Affirming Care

Starting in the late 1990s, clinicians in the Netherlands began using GnRH agonists for a different purpose: giving transgender adolescents time before their bodies developed in ways that felt deeply wrong to them. The idea was to press “pause” on puberty so the young person, their family, and their clinical team could have more time to explore the adolescent’s gender identity without the distress of irreversible physical changes like a deepening voice or breast growth.

Under most clinical protocols, puberty blockers for gender dysphoria can only be started after puberty has already begun, specifically after the adolescent has entered Tanner stage 2, which marks the earliest visible signs of pubertal development.⁶ The treatment is framed as a reversible first step that gives the adolescent breathing room before any decisions about cross-sex hormones or other interventions.⁷ In practice, research has examined whether starting pubertal blockade at those early Tanner stages is associated with better psychosocial outcomes; one study of 438 transgender and gender-diverse youth found that those who received pubertal blockade at Tanner stage 2 or 3 were compared to those who had not received it at those stages, contributing to the evidence base around timing.⁸

How They Are Delivered

Puberty blockers come in several forms, and the choice depends on the clinical setting, the child’s age, and practical factors like how often a family can make it to a clinic. The most common options are:

Monthly or three-monthly injections: Leuprolide acetate (Lupron) is the drug most people have heard of. It is injected into muscle or under the skin and slowly releases medication over weeks.
Subcutaneous implant: Histrelin (Supprelin LA) is a small, flexible rod inserted under the skin of the upper arm. It delivers a steady dose for about a year, though some clinicians leave it in longer.

One ten-year institutional review covering 377 patients and 866 procedures found that histrelin implantation in children is safe, with complications occurring in only about 1% of cases. Over time, the institution shifted procedures out of the operating room and into the outpatient clinic: by the second five years of the study, nearly two-thirds of implant procedures were done in a clinic setting under local anesthesia.⁹ Extended use of histrelin implants beyond the labeled period has also been reviewed, with the majority of removal procedures being uneventful. Complications were uncommon and generally minor, such as an implant breaking during extraction or being difficult to remove due to tissue encapsulation around it.¹⁰

What “Reversible” Actually Means

You will often hear that puberty blockers are “fully reversible.” The core of that claim is accurate in one important sense: when the medication is stopped, the hypothalamic-pituitary-gonadal axis restarts and puberty resumes. In children with precocious puberty, this is well documented. In transgender adolescents, the same hormonal rebound occurs. The clinical literature describes puberty suppression as the “reversible first step” of treatment precisely because hormone levels recover after discontinuation.⁷

But “the hormones come back” and “everything is exactly the same as if treatment never happened” are two different statements. Puberty is not just a set of hormone levels; it is a years-long developmental window during which bones mineralize, the brain restructures, fertility matures, and growth occurs on a specific trajectory. Pausing that window may leave traces even after hormones resume, and the research on several of these fronts is still evolving. The sections below cover what is currently known about each area of concern.

Effects on Bone Health

Bone mineral density is probably the best-studied concern. During normal puberty, rising sex hormones drive a rapid increase in bone density, especially at the spine and hips. When you suppress those hormones, that bone-building window slows or stalls. Research consistently shows a negative impact of long-term puberty suppression on bone mineral density, particularly at the lumbar spine, and the deficit is only partially restored even after sex hormones are later introduced.¹¹

A study published in JAMA Pediatrics tracked bone density z-scores (a measure comparing an individual’s bone density to the average for their age) through puberty suppression and into subsequent hormone therapy. For transgender girls (those assigned male at birth), lumbar spine z-scores dropped during suppression and remained meaningfully below average even after long-term estrogen use. For transgender boys (assigned female at birth), the picture was more reassuring: lumbar spine z-scores were closer to average after testosterone treatment.¹² This difference between the two groups is important and not fully explained, though it may partly reflect how testosterone and estrogen each affect bone differently during adolescence.

For children treated for precocious puberty, the bone density picture is less concerning. The study of girls with CPP treated to final height found that treatment improved height without compromising peak bone mass.⁴ The difference likely reflects the fact that CPP patients resume their own native puberty after treatment ends, whereas transgender adolescents typically move to cross-sex hormones, creating a different hormonal environment for bone recovery.

Fertility Considerations

Sex hormones drive the maturation of eggs and sperm. If puberty is paused before those germ cells have had a chance to mature, and the individual then moves directly to cross-sex hormones without a period of natural puberty in between, the long-term impact on fertility is unclear. Suppression of puberty with GnRH agonists can pause germ-cell maturation, and this may affect fertility potential.¹³

For children with precocious puberty who eventually stop the medication and go through puberty naturally, fertility does not appear to be compromised. The concern is specific to scenarios where a young person starts blockers early in puberty and transitions directly to cross-sex hormones without allowing their natal puberty to progress far enough for gamete maturation. Fertility preservation options like egg or sperm banking exist, but they depend on the individual being far enough into puberty to produce viable gametes, and the conversation about preservation needs to happen before treatment begins. This is one of the most significant counseling points in gender-affirming care for adolescents.

Brain Development and Cognitive Questions

Whether suppressing pubertal hormones affects brain development is one of the most difficult questions to answer, partly because adolescent brain maturation is extraordinarily complex and partly because good longitudinal studies in humans are scarce. A 2024 review found that in animal studies, the cognitive effects of puberty blockers were complex and often differed between sexes. The review concluded there was no evidence that cognitive effects are fully reversible after stopping treatment, and it noted some evidence of a negative impact on IQ in children, though it emphasized that no human studies had systematically explored the question with adequate baseline measurement and follow-up.¹⁴

Studies directly measuring cognitive performance in treated adolescents have been small and mixed. One neuroimaging study found no significant effect of GnRH agonist treatment on task performance (reaction times and accuracy) during a planning task in adolescents with gender dysphoria, though treated individuals assigned male at birth showed lower accuracy than some control groups. The study also observed that pubertal hormones may play a role in certain sex-related patterns of brain activation.¹⁵ Another study examining executive functioning in transgender youth found that long-duration pubertal suppression was associated with poorer executive function, while being on gender-affirming hormones was associated with better executive function. Anxiety symptoms and autism spectrum traits were also associated with poorer performance, making it hard to untangle causes.¹⁶

The honest summary is that the evidence here is thin and preliminary. Animal data raise plausible concerns, but human data are too limited to draw firm conclusions in either direction. Researchers and clinicians broadly agree this is an area that urgently needs better studies.

Mental Health Outcomes

Much of the debate around puberty blockers in gender-affirming care centers on mental health. Proponents argue the drugs relieve the distress of developing unwanted physical characteristics. Critics argue the evidence base is weak. Both positions have some truth.

A large two-year prospective study of 315 transgender and nonbinary youth receiving gender-affirming hormones (many of whom had previously received puberty blockers) found that appearance congruence, positive affect, and life satisfaction increased over the study period, while depression and anxiety symptoms decreased.¹⁷ A more recent analysis specifically tracking youth who initiated gender-affirming medical care with pubertal suppression found that depression symptoms and emotional health measures did not change significantly over 24 months, and at no point did average scores reach a clinically concerning range.¹⁸

These findings are encouraging but come with caveats. Most studies lack control groups of gender-dysphoric youth who did not receive treatment, making it hard to say definitively what the medication itself contributed versus other factors like therapeutic support, family acceptance, and social affirmation. A recent systematic review and meta-analysis noted that the overall certainty of the evidence regarding puberty blockers for gender dysphoria remains very low by formal grading standards, and that high-quality studies evaluating both short- and long-term outcomes are still needed.¹⁹ Several other systematic reviews have reached similar conclusions about the quality of available evidence.

Effects on Growth and Adult Height

Since sex hormones drive both the pubertal growth spurt and eventual growth-plate closure, suppressing them affects the growth trajectory. The direction and magnitude of that effect depend on the clinical context.

For transgender adolescents treated in Denmark, researchers observed that trans girls ended up significantly shorter than their target height (by about 2.7 cm on average), with a decline in growth velocity during GnRH agonist treatment that reversed once estrogen was started. Trans boys did not show the same decline in growth velocity during suppression and continued growing during their first year on testosterone.²⁰ In girls with genetic short stature and rapidly advancing puberty, a two-year course of pubertal suppression did not significantly alter predicted adult height or final height.²¹

The takeaway is that height outcomes vary based on when treatment starts, how long it lasts, what hormonal environment follows, and the individual’s own genetic growth potential. Clinicians typically monitor growth velocity and bone age throughout treatment to adjust the plan as needed.

Access, Cost, and Insurance

Even when a family and their medical team agree that puberty blockers are appropriate, getting the medication can be difficult. GnRH agonists are expensive: a year’s supply of injectable leuprolide or a histrelin implant can cost thousands of dollars without insurance, and insurance coverage varies widely. Research into the experiences of transgender youth has documented significant barriers to accessing appropriate hormone therapy, with insurance denials being common. Given the high rates of mental health concerns, self-harm, and school victimization among transgender adolescents, researchers have argued that clinicians and policymakers need to work toward insurance coverage reform.²²

In recent years, several U.S. states and some countries have introduced legislative restrictions on the use of puberty blockers for gender dysphoria in minors, while other jurisdictions have expanded access protections. The policy landscape is changing rapidly, and a family’s ability to access treatment can depend as much on geography as on medical judgment.

Uses Outside of Puberty

GnRH agonists and antagonists are not only prescribed to children. In adults, these drugs are a standard part of the medical toolkit for several conditions. Advanced prostate cancer, where tumor growth is fueled by testosterone, is treated with GnRH agonists to suppress androgen production. Endometriosis, a painful condition where uterine-lining tissue grows outside the uterus, can be managed with these drugs because the tissue responds to estrogen, and suppressing estrogen shrinks the growths. GnRH antagonists are also used routinely in in vitro fertilization to prevent premature ovulation during egg retrieval.²

These adult uses are worth knowing about because they undercut a common misconception that puberty blockers are an experimental drug category invented specifically for transgender care. The active medications have been in clinical use across multiple specialties for decades. What is newer, and where the evidence base is thinner, is their specific application to gender dysphoria in adolescents. The drug is well characterized; the question is whether this particular use, in this particular population, at this developmental stage, produces the outcomes that justify the trade-offs. That is the question researchers are still working to answer with the rigor the situation demands.

1
PubMed. Gonadotrophin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action
2
PubMed Central. GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy
3
Oxford Academic. Gonadotropin-Releasing Hormone Analog Design. Structure-Function Studies Toward the Development of Agonists and Antagonists: Rationale and Perspective
4
PubMed. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females
5
PubMed. Predictors of bone maturation, growth rate and adult height in children with central precocious puberty treated with depot leuprolide acetate
6
PubMed Central. Puberty suppression in adolescents with gender dysphoria: an emerging issue with multiple implications
7
PubMed. Transgender medicine – puberty suppression
8
PubMed. Association of Pubertal Blockade at Tanner 2/3 With Psychosocial Benefits in Transgender and Gender Diverse Youth at Hormone Readiness Assessment
9
PubMed. Histrelin implantation in the pediatric population: A 10-year institutional experience
10
PubMed Central. Extended Use of Histrelin Implant in Pediatric Patients
11
PubMed Central. Impact of gender-affirming treatment on bone health in transgender and gender diverse youth
12
PubMed Central. Bone Mineral Density in Transgender Adolescents Treated With Puberty Suppression and Subsequent Gender-Affirming Hormones
13
PubMed Central. Fertility concerns of the transgender patient
14
PubMed. The impact of suppressing puberty on neuropsychological function: A review
15
PubMed. Puberty suppression and executive functioning: An fMRI-study in adolescents with gender dysphoria
16
PubMed. Transgender Youth Executive Functioning: Relationships with Anxiety Symptoms, Autism Spectrum Disorder, and Gender-Affirming Medical Treatment Status
17
PubMed Central. Psychosocial Functioning in Transgender Youth after 2 Years of Hormones
18
PubMed Central. Mental and Emotional Health of Youth after 24 months of Gender-Affirming Medical Care Initiated with Pubertal Suppression
19
Archives of Disease in Childhood. Puberty blockers for gender dysphoria in youth: A systematic review and meta-analysis
20
The Journal of Clinical Endocrinology & Metabolism. Growth and Adult Height Attainment in Danish Transgender Adolescents Treated With GnRH Analog and Sex Hormones
21
PubMed Central. Effect of Pubertal Suppression on Linear Growth and Body Mass Index; a Two-Year Follow-Up in Girls with Genetic Short Stature and Rapidly Progressive Puberty
22
PubMed. Mental Health Concerns and Insurance Denials Among Transgender Adolescents